Maternal DHA Supplementation and Offspring Neurodevelopment in India (DHANI-2)

Inclusion Criteria: * Willing, healthy singleton gestation of ≤ 20 weeks (scan report must) * 18-35 years * Hb \> 7 g/dL * Non-fasting glucose as per Diabetes in Pregnancy Study Group of India (DIPSI) criteria (\<140mg/dL) * No history of chronic diseases (heart disease, diabetes, liver disorders, cancer, epilepsy, HIV, thyroid) or * High risk pregnancy (short stature\*\*, molar pregnancy++, HBsAg positive, as advised by physicians) * \<143 cm ++ A molar pregnancy starts when an egg is fertilized, but instead of a normal, viable pregnancy resulting, the placenta develops into an abnormal mass of cysts. Exclusion Criteria: * Women allergic (if aware) to any of the test products. * Women at high risk for hemorrhagic bleeding, clotting (if aware). * Women with high-risk pregnancies (history and prevalence of pregnancy complications, including abruptio placentae, preeclampsia, pregnancy-induced hypertension, any serious bleeding episode in the current pregnancy, and/ or physician referral); and/or diagnosed chronic degenerative disease(s) such as diagnosed heart disease, cancer, stroke or diabetes (as omega-3 could raise blood sugar and lower insulin production). * Women consuming omega-3 supplements or having used these in 3 months preceding the intervention period. * Reported participation in another biomedical trial 3 months before the start of the study or during the study (not to get the results of the present study contaminated).